Analyst Debanjana Chatterjee of JonesTrading reiterated a Buy rating on Intellia Therapeutics, retaining the price target of $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee’s rating is based on Intellia Therapeutics’ strategic advancements and promising clinical trial updates. The company is expanding its Phase 3 study for ATTR-CM, aiming to demonstrate significant benefits over existing stabilizers, which could position it favorably in the market. Additionally, Intellia’s ongoing trials in ATTR-PN and HAE are progressing with strong momentum, suggesting potential for positive clinical outcomes and catalysts through 2027.
Moreover, the upsizing of the MAGNITUDE study and the expected interim analysis could provide critical insights into the efficacy of their treatments. The anticipated data releases from various phases of their trials, including the long-term data for ATTR-PN and ATTR-CM, further support the potential for meaningful advancements. These factors collectively contribute to a favorable risk-reward profile, justifying the Buy rating and the price target of $25.
Chatterjee covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Opus Genetics, and Tvardi Therapeutics. According to TipRanks, Chatterjee has an average return of 22.5% and a 63.77% success rate on recommended stocks.